Poor Lilly. They have plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act and paid $36 million to settle charges of off-label promotion of its Evista osteoporosis treatment in 1998.
Government regulators charged the company with promoting its Evista product for two other uses -- the prevention of breast cancer and for reducing cardiovascular risk -- neither of which have been approved by the Food and Drug Administration.
Chairman and Chief Executive Sidney Taurel said in a statement that the company regrets the conduct and plans to "continue to take steps designed to assure that Lilly's promotional activities remain fully compliant."
In addition to the misdemeanor charge, the government has an ongoing civil complaint alleging that similar Evista-related conduct continued into 2000. Eli Lilly said it disagrees with the charges but has agreed to settle the dispute.
So thats alright then!
Source: theindychannel.com
No comments:
Post a Comment